Full access to medicines is hampered by a variety of factors. Two important barriers are high prices and regulatory issues such as long lag times in bringing medicines to market.
IGBA recommendations for action to support a sustainable global pharmaceutical market for continued patient access worldwide to safe, effective and high-quality medicines (October 2019)
The positive impact that generic and biosimilar medicines have on patients and health systems (October 2019)
- Op-ed: Trade agreement drug monopoly is obsolete given faster, better drug discovery
- IGBA Releases Trade Principles to Foster Trade in Generic and Biosimilar Medicines
- Committing to Global Health: Balancing Access and Sustainability key to success
- IGBA congratulates health Canada for decision on biologics naming that supports growing global consensus